- Home
- CUE vs IOBT Comparison
CUE vs IOBT Comparison
Compare CUE & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- IOBT
- Stock Information
- Founded
- CUE 2014
- IOBT 2014
- Country
- CUE United States
- IOBT Denmark
- Employees
- CUE N/A
- IOBT N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- IOBT Health Care
- Exchange
- CUE Nasdaq
- IOBT Nasdaq
- Market Cap
- CUE 61.1M
- IOBT 50.5M
- IPO Year
- CUE 2018
- IOBT 2021
- Fundamental
- Price
- CUE $0.70
- IOBT $0.85
- Analyst Decision
- CUE Strong Buy
- IOBT Buy
- Analyst Count
- CUE 2
- IOBT 4
- Target Price
- CUE $3.00
- IOBT $3.50
- AVG Volume (30 Days)
- CUE 267.2K
- IOBT 7.4M
- Earning Date
- CUE 11-13-2025
- IOBT 11-07-2025
- Dividend Yield
- CUE N/A
- IOBT N/A
- EPS Growth
- CUE N/A
- IOBT N/A
- EPS
- CUE N/A
- IOBT N/A
- Revenue
- CUE $8,286,000.00
- IOBT N/A
- Revenue This Year
- CUE N/A
- IOBT N/A
- Revenue Next Year
- CUE N/A
- IOBT N/A
- P/E Ratio
- CUE N/A
- IOBT N/A
- Revenue Growth
- CUE N/A
- IOBT N/A
- 52 Week Low
- CUE $0.54
- IOBT $0.32
- 52 Week High
- CUE $1.99
- IOBT $2.79
- Technical
- Relative Strength Index (RSI)
- CUE 39.09
- IOBT 46.05
- Support Level
- CUE $0.69
- IOBT $0.83
- Resistance Level
- CUE $0.81
- IOBT $1.23
- Average True Range (ATR)
- CUE 0.04
- IOBT 0.13
- MACD
- CUE -0.01
- IOBT 0.05
- Stochastic Oscillator
- CUE 6.00
- IOBT 43.53
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.